INS and metabolic dysfunction-associated steatotic liver disease: In addition, the treatment with the two drugs decreased the incidence of type 1 diabetes mellitus, T2DM, insulin resistance, glucagon signaling pathway, and nonalcoholic fatty liver disease (NAFLD; Figure 7).